Scotland-based sensor technology company Novosound has obtained a patent for its wearable ultrasonic instrumentation system.

The move comes as the company recently launched its related Slanj platform, which is aimed at the medical and wearable device sectors worldwide.

The patent provides Novosound with exclusive rights to market the imaging platform that has been pivotal in leading research in Scotland and the US into wireless, wearable ultrasound.

Novosound CEO and co-founder Dr Dave Hughes: “Alongside our commercial and R&D partners, we have been able to push the boundaries of innovation around ultrasound technology, what we describe as ultrasound, integrated, everywhere.

“This allows us to integrate and license the technology with smartwatch partners, looking deeper into the body and enhancing the measurements their optical and electrical sensors provide, opening up the holy grail of 24/7 blood pressure monitoring on the wrist.”

Novosound is also advancing patent applications for its wearable technology in various international markets.

Concurrently, research and pilot projects are ongoing with major technology corporations, including studies on muscle activity and blood pressure monitoring for smartwatch applications, collaborating with institutions such as the Texas Medical Centre.

Hughes added: “This technology builds on the legacy of ultrasound in Scotland, where it was first demonstrated as a medical diagnostic technique at the University of Glasgow in 1954, and now as a Scottish company moves it out of the hospital and into the home via a wearable device.”

The company is on track for its fourth consecutive year of revenue growth, with significant market expansion in North America. Since its inception as the University of the West of Scotland's first spinout in 2018, Novosound has raised more than £10m.

In 2022, Novosound signed a commercial partnership agreement with medical technology company Pavmed to advance intravascular imaging technology.